RESUMEN
Lysosomotropism is a biological characteristic of small molecules, independently present of their intrinsic pharmacological effects. Lysosomotropic compounds, in general, affect various targets, such as lipid second messengers originating from lysosomal enzymes promoting endothelial stress response in systemic inflammation; inflammatory messengers, such as IL-6; and cathepsin L-dependent viral entry into host cells. This heterogeneous group of drugs and active metabolites comprise various promising candidates with more favorable drug profiles than initially considered (hydroxy) chloroquine in prophylaxis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections/Coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) triggered by bacterial or viral infections. In this hypothesis, we discuss the possible relationships among lysosomotropism, enrichment in lysosomes of pulmonary tissue, SARS-CoV-2 infection, and transition to COVID-19. Moreover, we deduce further suitable approved drugs and active metabolites based with a more favorable drug profile on rational eligibility criteria, including readily available over-the-counter (OTC) drugs. Benefits to patients already receiving lysosomotropic drugs for other pre-existing conditions underline their vital clinical relevance in the current SARS-CoV2/COVID-19 pandemic.
Asunto(s)
Antivirales/farmacología , Tratamiento Farmacológico de COVID-19 , Descubrimiento de Drogas , Lisosomas/efectos de los fármacos , SARS-CoV-2/efectos de los fármacos , Bibliotecas de Moléculas Pequeñas/farmacología , Antivirales/farmacocinética , Antivirales/uso terapéutico , COVID-19/inmunología , COVID-19/metabolismo , COVID-19/virología , Clorpromazina/farmacocinética , Clorpromazina/farmacología , Clorpromazina/uso terapéutico , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Descubrimiento de Drogas/métodos , Reposicionamiento de Medicamentos/métodos , Fluvoxamina/farmacocinética , Fluvoxamina/farmacología , Fluvoxamina/uso terapéutico , Humanos , Hidroxicloroquina/farmacocinética , Hidroxicloroquina/farmacología , Hidroxicloroquina/uso terapéutico , Interleucina-1/antagonistas & inhibidores , Interleucina-1/inmunología , Interleucina-6/antagonistas & inhibidores , Interleucina-6/inmunología , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/metabolismo , Pulmón/virología , Lisosomas/inmunología , Lisosomas/metabolismo , Lisosomas/virología , SARS-CoV-2/inmunología , SARS-CoV-2/fisiología , Bibliotecas de Moléculas Pequeñas/farmacocinética , Bibliotecas de Moléculas Pequeñas/uso terapéutico , Replicación Viral/efectos de los fármacosRESUMEN
OBJECTIVES: The ongoing COVID-19 pandemic comprises a total of more than 2,350,000 cases and 160,000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (â¼4%) compared to health care professionals (â¼14%). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition, to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20-200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (30-100 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood-brain barrier and could therefore prevent the neurological forms of COVID-19. METHODS: Our hypothesis is that CPZ could decrease the unfavorable evolution of COVID-19 infection in oxygen-requiring patients without the need for intensive care, but also reduce the contagiousness of SARS-CoV-2. At this end, we designed a pilot, phase III, multicenter, single blind, randomized controlled clinical trial. Efficacy of CPZ will be assessed according to clinical, biological and radiological criteria. The main objective is to demonstrate a shorter time to response (TTR) to treatment in the CPZ+standard-of-care (CPZ+SOC) group, compared to the SOC group. Response to treatment is defined by a reduction of at least one level of severity on the WHO-Ordinal Scale for Clinical Improvement (WHO-OSCI). The secondary objectives are to demonstrate in the CPZ+SOC group, compared to the SOC group: (A) superior clinical improvement; (B) a greater decrease in the biological markers of viral attack by SARS-CoV-2 (PCR, viral load); (C) a greater decrease in inflammatory markers (e.g. CRP and lymphopenia); (D) a greater decrease in parenchymal involvement (chest CT) on the seventh day post-randomization; (E) to define the optimal dosage of CPZ and its tolerance; (F) to evaluate the biological parameters of response to treatment, in particular the involvement of inflammatory cytokines. Patient recruitment along with the main and secondary objectives are in line with WHO 2020 COVID-19 guidelines. CONCLUSION: This repositioning of CPZ as an anti-SARS-CoV-2 drug offers an alternative and rapid strategy to alleviate the virus propagation and the infection severity and lethality. This CPZ repositioning strategy also avoids numerous developmental and experimental steps and can save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easy to manage side effects. Indeed, CPZ is an FDA-approved drug with an excellent tolerance profile, prescribed for around 70 years in psychiatry but also in clinical routine in nausea and vomiting of pregnancy, in advanced cancer and also to treat headaches in various neurological conditions. The broad spectrum of CPZ treatment - including antipsychotic, anxiolytic, antiemetic, antiviral, immunomodulatory effects along with inhibition of clathrin-mediated endocytosis and modulation of blood-brain barrier - is in line with the historical French commercial name for CPZ, i.e. LARGACTIL, chosen as a reference to its "LARGe ACTion" properties. The discovery of those CPZ properties, as for many other molecules in psychiatry, is both the result of serendipity and careful clinical observations. Using this approach, the field of mental illness could provide innovative therapeutic approaches to fight SARS-CoV-2.
Asunto(s)
Antivirales/uso terapéutico , Betacoronavirus , Clorpromazina/uso terapéutico , Ensayos Clínicos Fase III como Asunto/métodos , Infecciones por Coronavirus/tratamiento farmacológico , Estudios Multicéntricos como Asunto/métodos , Pandemias , Neumonía Viral/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Antivirales/farmacocinética , Antivirales/farmacología , Biomarcadores , Barrera Hematoencefálica , COVID-19 , Clorpromazina/farmacocinética , Clorpromazina/farmacología , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Citocinas/sangre , Relación Dosis-Respuesta a Droga , Reposicionamiento de Medicamentos , Endocitosis/efectos de los fármacos , Francia/epidemiología , Humanos , Pulmón/metabolismo , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/epidemiología , Selección de Paciente , Proyectos Piloto , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Proyectos de Investigación , SARS-CoV-2 , Saliva/metabolismo , Índice de Severidad de la Enfermedad , Método Simple Ciego , Distribución Tisular , Tratamiento Farmacológico de COVID-19Asunto(s)
Betacoronavirus , Clorpromazina , Infecciones por Coronavirus/tratamiento farmacológico , Pulmón , Fenotiazinas , Neumonía Viral/tratamiento farmacológico , Trastornos Psicóticos/tratamiento farmacológico , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapéutico , Betacoronavirus/efectos de los fármacos , Betacoronavirus/fisiología , Disponibilidad Biológica , Investigación Biomédica , COVID-19 , Clorpromazina/farmacocinética , Clorpromazina/uso terapéutico , Infecciones por Coronavirus/metabolismo , Reposicionamiento de Medicamentos/métodos , Humanos , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Concentración Máxima Admisible , Evaluación de Necesidades , Pandemias , Fenotiazinas/farmacocinética , Fenotiazinas/uso terapéutico , Neumonía Viral/metabolismo , SARS-CoV-2 , Distribución TisularRESUMEN
Curating the data underlying quantitative structure-activity relationship models is a never-ending struggle. Some curation can now be automated but much cannot, especially where data as complex as those pertaining to molecular absorption, distribution, metabolism, excretion, and toxicity are concerned (vide infra). The authors discuss some particularly challenging problem areas in terms of specific examples involving experimental context, incompleteness of data, confusion of units, problematic nomenclature, tautomerism, and misapplication of automated structure recognition tools.
Asunto(s)
Curaduría de Datos , Relación Estructura-Actividad Cuantitativa , Clorpromazina/química , Clorpromazina/farmacocinética , Sistema Enzimático del Citocromo P-450/metabolismo , Exactitud de los Datos , Isomerismo , Metilergonovina/química , Midazolam/análogos & derivados , Midazolam/química , Estructura Molecular , Terminología como Asunto , Termodinámica , Temperatura de TransiciónRESUMEN
BACKGROUND: Symptom management medications are often compounded into topical gel formulations providing an alternative route of administration for hospice and palliative care patients. Though commonly used, transdermal absorption and bioavailability studies of these gel products are lacking. Chlorpromazine was studied because it is FDA approved for treatment of nausea and vomiting and is used off-label for treatment of agitation and delirium. OBJECTIVE: The objective of this study is to determine the transdermal absorption of chlorpromazine PLO gel in healthy adults. METHODS: Twenty-five milligrams of chlorpromazine in PLO gel was applied to 10 subjects' wrists and 100 mg was applied to 1 subject's wrist. Blood draws were completed preapplication and 1, 2, and 4 hours postapplication. This single-center unblinded study recruited healthy adults between 18 and 70 years of age. Participants were not pregnant, did not have an allergy to any component of the study medication, and were not taking a phenothiazine medication. RESULTS: Chlorpromazine was undetected in any of the 11 subjects' blood samples. LIMITATIONS: There is an assumption of equivalent medication absorption in healthy patients and palliative care or hospice patients. CONCLUSION: Rapid relief of symptoms at end of life is essential. Chlorpromazine in PLO gel may not be an effective treatment option since blood levels were undetectable at 1, 2, and 4 hours after topical application.
Asunto(s)
Clorpromazina/farmacocinética , Adulto , Disponibilidad Biológica , Química Farmacéutica , Femenino , Geles , Humanos , Masculino , Persona de Mediana Edad , Absorción CutáneaRESUMEN
BACKGROUND: Cytochrome P450 2D6 enzyme (CYP2D6) is an important metabolic pathway for many antipsychotics. Its genetic polymorphism causes pharmacokinetic variability that might lead to adverse drug reactions or treatment failure unless countered by appropriate dose adjustments or shift to CYP2D6-independent antipsychotics. PURPOSE: To investigate the clinical impact of CYP2D6 genotype in patients with a diagnosis within the schizophrenic spectrum using medication pattern as proxy for therapeutic and side effect. METHODS: The study was conducted in patients genotyped during an inpatient stay (N = 576). Continuous antipsychotic, adjuvant, and anticholinergic drug regimens were registered retrospectively in a cross-sectional manner before genotyping. Antipsychotics were divided into CYP2D6 dependent and independent, and dose equivalents were calculated as chlorpromazine equivalents (CPZEq). RESULTS: Poor metabolizers and ultrarapid metabolizers were treated with significantly higher median CPZEq doses (625.8; inter quartile range [IQR], 460.4-926.7; and 550; IQR, 199.8-1049) than extensive metabolizers (EMs) and intermediate metabolizers (IMs) (384; IQR, 150-698; and 446; IQR, 150-800) (P = 0.018). Logistic regression showed no association between anticholinergic treatment and CYP2D6 genotype or concomitant treatment with CYP2D6 inhibitors (P = 0.79 and P = 0.46, respectively). CONCLUSIONS: Our results indicate that CYP2D6 genotype has no sufficient clinical impact that poor metabolizers and ultrarapid metabolizers are easily clinically identified with.
Asunto(s)
Antipsicóticos/efectos adversos , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapéutico , Clorpromazina/farmacocinética , Clorpromazina/uso terapéutico , Citocromo P-450 CYP2D6/genética , Genotipo , Polimorfismo Genético/genética , Esquizofrenia/diagnóstico , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/genética , Psicología del Esquizofrénico , Adulto , Clorpromazina/efectos adversos , Estudios Transversales , Dinamarca , Relación Dosis-Respuesta a Droga , Femenino , Pruebas Genéticas , Humanos , Inactivación Metabólica , Masculino , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
INTRODUCTION: Urgent action is needed to fight the ongoing coronavirus disease 2019 (COVID-19) pandemic by reducing the number of infected cases, contagiousness and severity. Chlorpromazine (CPZ), an antipsychotic from the phenothiazine group, is known to inhibit clathrin-mediated endocytosis and has antiviral activity against severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus. The aim of this in-vitro study was to test CPZ against SARS-CoV-2 in monkey and human cells. MATERIALS AND METHODS: Monkey VeroE6 cells and human alveolar basal epithelial A549-ACE2 cells were infected with SARS-CoV-2 in the presence of various concentrations of CPZ. Supernatants were harvested at day 2 and analysed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) for the presence of SARS-CoV-2 RNA. Cell viability was assessed in non-infected cells. RESULTS: CPZ was found to have antiviral activity against SARS-CoV-2 in monkey VeroE6 cells, with a half maximal inhibitory concentration (IC50) of 8.2 µM, half maximal cytotoxic concentration (CC50) of 13.5 µM, and selectivity index (SI) of 1.65. In human A549-ACE2 cells, CPZ was also found to have anti-SARS-CoV-2 activity, with IC50 of 11.3 µM, CC50 of 23.1 µM and SI of 2.04. DISCUSSION: Although the measured SI values are low, the IC50 values measured in vitro may translate to CPZ dosages used in routine clinical practice because of the high biodistribution of CPZ in lungs and saliva. Also, the distribution of CPZ in brain could be of interest for treating or preventing neurological and psychiatric forms of COVID-19. CONCLUSIONS: These preclinical findings support clinical investigation of the repurposing of CPZ, a drug with mild side effects, in the treatment of patients with COVID-19.
Asunto(s)
Antivirales/farmacología , Clorpromazina/farmacología , Reposicionamiento de Medicamentos , SARS-CoV-2/efectos de los fármacos , Replicación Viral/efectos de los fármacos , Células A549 , Animales , Línea Celular , Chlorocebus aethiops , Clorpromazina/farmacocinética , Humanos , Distribución Tisular , Células Vero , Tratamiento Farmacológico de COVID-19RESUMEN
This study examined the accumulation and metabolism of a number of drugs and commonly used probes for human cytochrome P450s (CYPs) in zebrafish larvae under conditions relevant to pharmacological and toxicological assays. Studies with cisapride, chlorpromazine, verapamil, testosterone, and dextromethorphan showed that the zebrafish larvae catalyze a range of phase 1 (oxidation, N-demethylation, O-de-ethylation, and N-dealkylation) and phase 2 (sulfation and glucuronidation) reactions. Both similarities and differences in the metabolic pathways were observed in zebrafish larvae when compared to mammals. Metabolism of phenacetin to paracetamol and dextromethorphan to dextrorphan (metabolic reactions catalyzed by CYP 1A2 and 2D6 in humans respectively) were observed in the zebrafish larvae. In addition the zebrafish larvae 7 days post fertilization (7 d.p.f.) hydroxylated diclofenac, bupropion, tacrine, and testosterone. Although metabolites of several compounds were detected in zebrafish larvae, in the instances where the metabolite amounts were quantified, the amount of any specific metabolite formed was low, accounting for only a small percentage of the amount of parent compound added. Furthermore, when the concentrations of metabolite present in the zebrafish larvae were compared with the measured level of parent compound, the metabolite concentrations were always much lower than that of parent compound. Overall, for the compounds used in the current study it is unlikely that the quantified metabolites would significantly contribute to the outcome of safety pharmacology or toxicology studies conducted in zebrafish larvae under the paradigms typically used for such investigations.
Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Farmacocinética , Pez Cebra/metabolismo , Animales , Clorpromazina/farmacocinética , Cisaprida/farmacocinética , Larva/metabolismo , Preparaciones Farmacéuticas/metabolismo , Especificidad por Sustrato , Verapamilo/farmacocinética , Pez Cebra/crecimiento & desarrolloRESUMEN
OBJECTIVES: The association between anticholinergic load-based Anticholinergic Risk Scale scores and nutritional status is unclear in Japanese patients. The aim of this study was to establish whether anticholinergic load affects the nutritional status of geriatric patients in convalescent stages. DESIGN: Retrospective longitudinal cohort study. SETTING: Convalescent rehabilitation wards. PARTICIPANTS: Of the 1490 patients aged ≥65 years who were discharged from convalescent rehabilitation wards between July 2010 and October 2018, 908 patients met the eligibility criteria. They were categorized according to the presence or absence of increased anticholinergic load from admission to discharge. MEASUREMENTS: Demographic data, laboratory data, the Functional Independence Measure were analyzed between the groups. The primary outcome was Geriatric Nutritional Risk Index (GNRI) at discharge. Multiple linear regression analysis was performed to analyze the relationship between anticholinergic load and GNRI at discharge. RESULTS: Multiple linear regression analysis after adjusting for confounding factors revealed that anticholinergic load was independently and negatively correlated with GNRI at discharge. Particularly, the use of chlorpromazine, hydroxyzine, haloperidol, metoclopramide, risperidone, etc. increased significantly from admission to discharge. CONCLUSION: Increased anticholinergic load during hospitalization may be a predictor of nutritional status in geriatric patients.
Asunto(s)
Antagonistas Colinérgicos/sangre , Antagonistas Colinérgicos/farmacocinética , Desnutrición/epidemiología , Estado Nutricional/fisiología , Anciano , Anciano de 80 o más Años , Clorpromazina/farmacocinética , Antagonistas Colinérgicos/uso terapéutico , Femenino , Evaluación Geriátrica , Haloperidol/farmacocinética , Hospitalización , Humanos , Hidroxizina/farmacocinética , Japón/epidemiología , Modelos Lineales , Estudios Longitudinales , Masculino , Metoclopramida/farmacocinética , Análisis Multivariante , Evaluación Nutricional , Alta del Paciente , Análisis de Regresión , Estudios Retrospectivos , Risperidona/farmacocinéticaRESUMEN
Transient absorption spectroscopy in combination with in silico methods has been employed to study the interactions between human serum albumin (HSA) and the anti-psychotic agent chlorpromazine (CPZ) as well as its two demethylated metabolites (MCPZ and DCPZ). Thus, solutions containing CPZ, MCPZ or DCPZ and HSA (molar ligand:protein ratios between 1:0 and 1:3) were submitted to laser flash photolysis and the ΔAmax value at λâ¯=â¯470â¯nm, corresponding to the triplet excited state, was monitored. In all cases, the protein-bound ligand exhibited higher ΔAmax values measured after the laser pulse and were also considerably longer-lived than the non-complexed forms. This is in agreement with an enhanced hydrophilicity of the metabolites, due to the replacement of methyl groups with H that led to a lower extent of protein binding. For the three compounds, laser flash photolysis displacement experiments using warfarin or ibuprofen indicated Sudlow site I as the main binding site. Docking and molecular dynamics simulation studies revealed that the binding mode of the two demethylated ligands with HSA would be remarkable different from CPZ, specially for DCPZ, which appears to come from the different ability of their terminal ammonium groups to stablish hydrogen bonding interactions with the negatively charged residues within the protein pocket (Glu153, Glu292) as well as to allocate the methyl groups in an apolar environment. DCPZ would be rotated 180° in relation to CPZ locating the aromatic ring away from the Sudlow site I of HSA.
Asunto(s)
Clorpromazina/química , Clorpromazina/farmacocinética , Albúmina Sérica Humana/química , Albúmina Sérica Humana/metabolismo , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Antipsicóticos/química , Antipsicóticos/farmacocinética , Sitios de Unión , Carbazoles/química , Carbazoles/farmacocinética , Clorpromazina/análogos & derivados , Clorpromazina/farmacología , Interacciones Farmacológicas , Humanos , Enlace de Hidrógeno , Inactivación Metabólica , Metilación , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Unión Proteica/efectos de los fármacos , Albúmina Sérica Humana/efectos de los fármacos , Espectrofotometría Ultravioleta , EstereoisomerismoRESUMEN
Chlorpromazine is known to deposit in ocular tissues when taken at high doses for prolonged periods. Chlorpromazine therapy in a 59-year-old schizophrenic man with a cumulative dosage exceeding 2500 g resulted in multiple white deposits in both corneas especially in the endothelium. Confocal microscopy revealed significant pleomorphism and polymegethism of endothelial cells. The anterior lens capsules opacities were star-shaped and concentrated in the centre. Because of cataract and chronic angle closure glaucoma our high-myopic patient underwent surgery, and light microscopic evaluation of the obtained anterior lens capsule during cataract surgery showed golden brown cytoplasmic deposits in the central epithelial cells and capsule. The peripheral epithelial cells of the removed capsule had no deposit. There were no sign of retinal deposits in the fundoscopy, optical coherence tomography and fluorescein angiography. In this patient chlorpromazine deposited mainly in the corneal endothelium, central anterior lens capsule and epithelial cells.
Asunto(s)
Antipsicóticos/administración & dosificación , Antipsicóticos/farmacocinética , Clorpromazina/administración & dosificación , Clorpromazina/farmacocinética , Ojo/metabolismo , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/metabolismo , Antipsicóticos/uso terapéutico , Clorpromazina/uso terapéutico , Esquema de Medicación , Endotelio Corneal/metabolismo , Células Epiteliales/metabolismo , Ojo/patología , Humanos , Cristalino/metabolismo , Masculino , Microscopía , Microscopía Confocal , Persona de Mediana Edad , Distribución TisularRESUMEN
The in vitro iontophoretic transdermal delivery of chlorpromazine (CPZ) across pig skin was investigated. Anodal iontophoresis considerably increased CPZ skin penetration and accumulation compared with the passive controls. The effect of CPZ concentration in the donor solution was studied (1.4-8.2 mM). A higher penetration was observed with an increase of the concentration. In addition, the effect of NaCl concentration was also studied (154-200 mM). As expected, CPZ iontophoretic transport decreased with NaCl content. Finally, the influence of the current density (0.20-0.50 mA/cm(2)) was investigated. The iontophoretic transport of CPZ tends to increase with current density, although this effect was not statistically significant between 0.35 and 0.5 mA/cm(2). On the whole, this work shows that iontophoresis may be used to improve the transdermal delivery of CPZ for the treatment of chronic psychosis.
Asunto(s)
Antipsicóticos/farmacocinética , Clorpromazina/farmacocinética , Iontoforesis , Absorción Cutánea , Administración Cutánea , Animales , Antipsicóticos/administración & dosificación , Clorpromazina/administración & dosificación , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Trastornos Psicóticos/tratamiento farmacológico , Piel/metabolismo , Cloruro de Sodio/química , PorcinosRESUMEN
A specific and sensitive capillary liquid chromatography-ultraviolet detection (cap-LC-UV) method in combination with a micro-extraction by packed sorbent (MEPS) sample clean-up procedure has been developed and validated for the simultaneous analysis of chlorpromazine, olanzapine and their flavin-containing monooxygenase (FMO) mediated N-oxides in rat brain microdialysates. Chromatographic separation was obtained on an Acclaim Pepmap RP C18 column with an ID of 300µm. An injection volume of 20µL was used to inject the largely aqueous samples and was shown to have no influence on the obtained peak shape of the compounds of interest. Optimal conditions for MEPS extraction were obtained on a mixed-mode M1 (80% C8, 20% SCX) cartridge after diluting microdialysate samples with phosphate buffer pH 2.5 (1:3 v/v). The method was validated and lower limits of quantification (LLOQ) were determined at 0.5nM for all compounds. Linearity was demonstrated between the LLOQ and 1µM for all compounds (R2>0.995). MEPS recoveries were between 92% and 98%, with intra- and interday variabilities below 15%. The applicability of the developed method was successfully demonstrated by analysing rat brain microdialysates. The capillary LC-UV method in combination with MEPS sample treatment provides a simple, sensitive method to quantify all compounds of interest in 45min and can be applied for routine therapeutic monitoring and pharmacokinetic studies of olanzapine, chlorpromazine and their respective N-oxides.
Asunto(s)
Benzodiazepinas/análisis , Encéfalo/metabolismo , Clorpromazina/análisis , Cromatografía Líquida de Alta Presión/métodos , Soluciones para Diálisis/química , Animales , Antipsicóticos/análisis , Antipsicóticos/farmacocinética , Benzodiazepinas/farmacocinética , Clorpromazina/farmacocinética , Masculino , Microdiálisis/métodos , Olanzapina , Oxidación-Reducción , Óxidos/análisis , Oxigenasas/metabolismo , Ratas Wistar , Reproducibilidad de los ResultadosRESUMEN
When zotepine, an antipsychotic drug, was electrochemically oxidized using electrospray ionization mass spectrometry (ESI-MS) coupled with a microflow electrolytic cell, [M + 16 + H]+ (m/z 348), [M-H]+ (m/z 330) and [M-14 + H]+ (m/z 318) were observed as electrochemical oxidation product ions (M represents the zotepine molecule). Although a major fragment ion that was derived from the dimethyl aminoethyl moiety was observed only at m/z 72 in the collision-induced dissociation (CID) spectrum of zotepine, new fragments such as m/z 315 and 286 ions could be generated in the CID spectrum by combining electrochemical oxidation and CID. Since these fragments were relatively specific with high ion strength, it was thought that they would be useful for developing a sensitive LC-MS/MS assay. The S-oxide and N-demethylated products were detected by electrolysis assuring that a portion of P450 metabolites of zotepine could be mimicked by the electrochemistry/electrospray ionization mass spectrometry (EC/ESI-MS) system.
Asunto(s)
Antipsicóticos/química , Antipsicóticos/farmacocinética , Dibenzotiepinas/química , Dibenzotiepinas/farmacocinética , Espectrometría de Masa por Ionización de Electrospray/métodos , Clorpromazina/química , Clorpromazina/farmacocinética , Oxidación-Reducción , Espectrometría de Masa por Ionización de Electrospray/instrumentaciónRESUMEN
Alpha(1)-acid glycoprotein (AGP) is a glycoprotein that consists of 183 amino acid residues and five carbohydrate chains and binds to neutral and basic drugs. We examined the structural properties and ligand-binding capacity of AGP in interactions with reverse micelles. Also, detailed information was obtained by comparing several different states of AGP. Interaction with reverse micelles induced a unique conformational transition (beta-sheet to alpha-helices) in AGP and decreased the binding capacity for the basic drug, chlorpromazine and the steroid hormone, progesterone to AGP. These structural conformations are very similar to those observed under conditions of acidity and high ionic strength (pH 2.0, 1.5 M NaCl). This structure seems to be an intermediate between the native state and the denatured state, possibly a molten globule. The present results suggest that when AGP interacts with the biomembrane, it undergoes a structural transition to a unique structure that differs from the native and denatured states and has a reduced ligand-binding capacity.
Asunto(s)
Micelas , Orosomucoide/química , Orosomucoide/metabolismo , Clorpromazina/farmacocinética , Dicroismo Circular , Dicumarol/farmacocinética , Cinética , Progesterona/farmacocinética , Unión Proteica , Conformación Proteica , Estructura Secundaria de ProteínaRESUMEN
Since drug induced liver injury is difficult to predict in animal models, more representative tests are needed to better evaluate these effects in humans. Existing in vitro systems hold great potential to detect hepatotoxicity of pharmaceuticals. In this study, the in vitro biokinetics of the model hepatotoxicant chlorpromazine (CPZ) were evaluated in three different liver cell systems after repeated exposure in order to incorporate repeated-dose testing into an in vitro assay. Primary rat and human hepatocytes, cultured in sandwich configuration and the human HepaRG cell line were treated daily with CPZ for 14 days. Samples were taken from medium, cells and well plastic at specific time points after the first and last exposure. The samples were analysed by HPLC-UV to determine the amount of CPZ in these samples. Based on cytotoxicity assays, the three models were tested at 1-2 µM CPZ, while the primary rat hepatocytes and the HepaRG cell line were in addition exposed to a higher concentration of 15-20 µM. Overall, the mass balance of CPZ decreased in the course of 24 h, indicating the metabolism of the compound within the cells. The largest decrease in parent compound was seen in the primary cultures; in the HepaRG cell cultures the mass balance only decreased to 50%. CPZ accumulated in the cells during the 14-day repeated exposure. Possible explanations for the accumulation of CPZ are a decrease in metabolism over time, inhibition of efflux transporters or binding to phospholipids. The biokinetics of CPZ differed between the three liver cell models and were influenced by specific cell properties as well as culture conditions. These results support the conclusion that in vitro biokinetics data are necessary to better interpret chemical-induced cytotoxicity data.
Asunto(s)
Clorpromazina/farmacocinética , Antagonistas de Dopamina/farmacocinética , Hepatocitos/metabolismo , Animales , Línea Celular , Clorpromazina/administración & dosificación , Antagonistas de Dopamina/administración & dosificación , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Humanos , RatasRESUMEN
Neurotoxic effects of compounds can be tested in vitro using cell systems. One example is aggregating rat brain cell cultures. For the extrapolation of in vitro data to the in vivo situation, it is important to take the biokinetics of the test compound into account. In addition, the exposure in vivo is often for a longer period of time; therefore, it is crucial to incorporate this into in vitro assays as well. In this study, aggregating rat brain cell cultures were exposed to chlorpromazine (CPZ) and diazepam (DZP) for 12-days with repeated exposure. Samples were taken from the stocks, test media, cell culture media and cells at specific time points on the first and last exposure day. These samples were analysed by HPLC-UV. The amount of CPZ in the medium decreased over time, whereas the amount in the cells showed an increase. Accumulation of CPZ in the cells was seen over the 12-day repeated exposure. The amount of DZP in the medium remained stable over time and only up to 2% of DZP added was found in the cells. Different biokinetic behaviour was found for CPZ and DZP. Possible explanations are differences in uptake into the cells or efflux out of the cells. The decrease of CPZ in the medium versus the stable amount of DZP results in differences in exposure concentrations over time, which should be taken into account when interpreting in vitro effect data.
Asunto(s)
Encéfalo/citología , Clorpromazina/farmacocinética , Diazepam/farmacocinética , Antagonistas de Dopamina/farmacocinética , Moduladores del GABA/farmacocinética , Neuronas/metabolismo , Animales , Células Cultivadas , Clorpromazina/administración & dosificación , Diazepam/administración & dosificación , Antagonistas de Dopamina/administración & dosificación , Moduladores del GABA/administración & dosificación , RatasRESUMEN
BACKGROUND: In humans, the excitability of the electrically evoked blink reflex is influenced by the subject's attention to the stimulus. The early reflex component R1 has been found to be facilitated in conditions of increased selective attention, whereas the late components R2 and R3 exhibited a marked suppression. Distraction from the stimulus leads to enhanced R2 and R3 magnitudes. METHODS: We investigated the excitability of the distinct reflex components in 19 patients with schizophrenia and 19 healthy control subjects. In the control condition (EE), stimulation was elicited by the experimenter; in a second condition (SE), subjects released a key to evoke the reflex themselves. RESULTS: The SE patients with schizophrenia exhibited an abnormally increased R1 facilitation and an impaired R2 inhibition in comparison with normal control subjects. An R3 component could be registered in EE in 13 of 19 patients but only in one control subject; SE resulted in a complete suppression of this component in all but two patients with schizophrenia. CONCLUSIONS: The abnormal R1 facilitation and the impaired R2 inhibition may be regarded as neurophysiological markers of defective information processing in a condition of increased selective attention to a self-controlled stimulus in patients with schizophrenia. The enhanced excitability of the R3 component under standard conditions indicates defective attentional mechanisms in patients with schizophrenia in an uninstructed passive condition attending a stimulus triggered by the experimenter.
Asunto(s)
Antipsicóticos/uso terapéutico , Parpadeo/fisiología , Esquizofrenia/fisiopatología , Adulto , Análisis de Varianza , Antipsicóticos/farmacocinética , Parpadeo/efectos de los fármacos , Estudios de Casos y Controles , Clorpromazina/farmacocinética , Estimulación Eléctrica , Electrofisiología , Femenino , Humanos , Masculino , Inhibición Neural , Esquizofrenia/tratamiento farmacológico , Índice de Severidad de la EnfermedadRESUMEN
An indirect approach to the relationship among drug dose, plasma level, and the competition between a labeled neuroleptic drug [18F]N-methylspiroperidol (18F-NMS) for binding sites in striatal tissue in normal and schizophrenic subjects is described. The slope of the line plotting the ratio of activity in the striatum (As) to activity in the cerebellum (Ac) versus time up to 5 hr postinjection of 18F-NMS is taken as a marker of site occupancy. An inverse relation between labeled competitor uptake and drug plasma level has been demonstrated for the classes of antipsychotic drug studied. Striatal uptake studies showed a progressive increase in all subjects following drug withdrawal up to 156 hr postwithdrawal. Uptake and clearance of 18F-NMS in cerebellar tissue was not appreciably affected by antipsychotic medication or drug withdrawal.
Asunto(s)
Clorpromazina/uso terapéutico , Cuerpo Estriado/efectos de los fármacos , Haloperidol/uso terapéutico , Receptores Dopaminérgicos/efectos de los fármacos , Esquizofrenia/tratamiento farmacológico , Espiperona/análogos & derivados , Tomografía Computarizada de Emisión , Adulto , Unión Competitiva , Clorpromazina/farmacocinética , Cuerpo Estriado/metabolismo , Haloperidol/farmacocinética , Humanos , Masculino , Persona de Mediana Edad , Receptores Dopaminérgicos/metabolismo , Receptores de Dopamina D2 , Espiperona/metabolismoRESUMEN
OBJECTIVE: This study examined the binding to cortical serotonin 5-HT2A receptors of conventional doses of the typical neuroleptic chlorpromazine in comparison with clozapine, the prototype atypical antipsychotic, and amisulpride, a specific dopamine D2-D3 blocker. METHOD: Seventeen schizophrenic patients treated with chlorpromazine (75-700 mg/day), four treated with clozapine (200-600 mg/day), and five treated with amisulpride (200-1200 mg/day) were studied. Cortical 5-HT2A binding was estimated by reference to the values for 14 antipsychotic-free schizophrenic subjects with the use of positron emission tomography and [18F]setoperone, a high-affinity radioligand for cortical 5-HT2A receptors. RESULTS: A dose-dependent decrease in the number of available cortical binding sites for [18F] setoperone was demonstrated in the chlorpromazine group; for the highest dose, there was a virtual lack of sites available for binding. A very low percentage of available binding sites was also observed in the clozapine-treated patients at all doses. This suggests a high level of 5-HT2A blockade with both clozapine and high doses of chlorpromazine. No significant binding of amisulpride to 5-HT2A receptors was detected. CONCLUSIONS: A high level of 5-HT2A receptor blockade does not appear specific to clozapine in comparison with high doses of chlorpromazine, suggesting that the distinct clinical profiles of both drugs are unrelated to 5-HT2A blockade itself.